Savara, Inc. (NASDAQ:SVRA) Financings

Savara, Inc.

Financings

RaiseDate
Public offering of common stock
Closed: US$149.5M raised
Use of proceeds: Accelerate investment in preparing for potential commercialization of MOLBREEVI
Nov 12, 2025
Royalty on U.S. net sales of MOLBREEVI
Announced: US$75M
Buyers: RTW ($75 million royalty funding; tiered single digit percentage of annual U.S. net sales of MOLBREEVI, subject to a cap)
Use of proceeds: Support the potential U.S. launch and commercialization of MOLBREEVI in autoimmune PAP
Oct 29, 2025

Read by 6ix AI from the company's releases